| 產(chǎn)品名稱 |
C1R-neo |
| 商品貨號 |
B164077 |
| Organism |
Homo sapiens, human |
| Cell Type |
B lymphoblast; Epstein-Barr virus (EBV) transforme |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 Cells contain herpesvirus
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
C1R-neo is a stable transfectant cell line established in 1987 by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo. C1R-neo does not secrete or express HLA B7. B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy. C1R-neo may be used as a control for C1R-sB7 (CRL-2370), in CTL experiments and for producing control supernatants. |
| Derivation |
C1R-neo is a stable transfectant cell line established in 1987 by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo. The vector did not carry an insert. C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. |
| Comments |
C1R-neo is a stable transfectant cell line established in 1987 by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo. The vector did not carry an insert. C1R-neo does not secrete or express HLA B7. C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. C1R-neo may be used as a control for C1R-sB7 (CRL-2370), in CTL experiments and for producing control supernatants. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 X 10(5) viable cells/ml. Maintain cultures at cell concentrations between 5 X 10(5) and 2 X 10(6) viable cells/ml. |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| STR Profile |
Amelogenin: X CSF1PO: 6,10 D13S317: 11,13 D16S539: 9,13 D5S818: 10,13 D7S820: 7,12 THO1: 8 TPOX: 8 vWA: 17 |
| Name of Depositor |
F Grumet |
| Year of Origin |
1987 |
| References |
Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
|
